Diflucan^® Partnership Program

Definition of Program Offer
Pfizer Inc makes available free of charge its antifungal medicine, Diflucan® (fluconazole), for the treatment of Cryptococcal meningitis and Esophageal candidiasis, two opportunistic infections associated with HIV/AIDS, to governmental and non-governmental organizations in more than 80 eligible countries in need. Countries with a greater than 1 percent HIV/AIDS prevalence will be given priority. The program has no time or dollar limit.

Diflucan® for donation is available in the following dosage forms: 200 mg tablets (pink in color), 200 mg intravenous vials, and 50 mg/5 ml powder for oral suspension for pediatric use.

The Diflucan Partnership Program also includes the training of health professionals in the diagnosis and treatment of opportunistic infections.

To Apply
Governments and non-governmental organizations interested in applying to receive Diflucan® should                click here to access the necessary documentation. Axios International, an international consultancy specialized in chronic disease management and drug delivery in developing countries, is managing the application process on behalf of Pfizer.